Product Name: 4,6-Dichloro-5-nitro-2-propylthiopyrimidine CAS NO:145783-14-8
Chemical & Physical Properties:
Appearance : Yellow power
Boiling Point:377.8℃ at 760 mmHg
Intermediate of Ticagrelor.
Ticagrelor is a new type of antiplatelet agglutinant, which was successfully developed by AstraZeneca in the United States. It is the world's first reversible combined oral P2Y12 adenosine diphosphate receptor antagonist, which is reversible It acts on the purinoceptor2 (P2) subtype P2Y12 on vascular smooth muscle cells (VSMC), does not require metabolic activation, has a significant inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), and is used orally The effect is rapid afterwards and can effectively improve the symptoms of patients with acute coronary heart disease.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.